Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT02139033 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

Start date: May 2014
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy of Retaine™ ophthalmic emulsion in treating the signs and symptoms of dry eye syndrome.

NCT ID: NCT02121301 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

NCT ID: NCT02117687 Completed - Dry Eye Syndromes Clinical Trials

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Start date: May 14, 2014
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

NCT ID: NCT02066896 Recruiting - XEROSTOMIA Clinical Trials

Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome

Start date: May 2014
Phase: Phase 3
Study type: Interventional

This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.

NCT ID: NCT02057822 Recruiting - Healthy Children Clinical Trials

Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months

Start date: November 2013
Phase: N/A
Study type: Observational

The ocular surface may be the seat of an inflammatory process in many pathology as vernal keratoconjunctivitis. It has been shown that inflammatory cytokines produced by the cells themselves and the constituent cells of the target organ, are the main factors that cause inflammation. The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects.

NCT ID: NCT02051023 Completed - Dry Eye Clinical Trials

Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)

FML
Start date: February 2014
Phase: Phase 3
Study type: Interventional

Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.

NCT ID: NCT02040623 Completed - Clinical trials for Chronic Graft-versus-host Disease

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)

DROPS-2
Start date: March 2014
Phase: Phase 2
Study type: Interventional

- To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures. - To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.

NCT ID: NCT01977443 Completed - Clinical trials for Viral Conjunctivitis

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

Start date: November 2013
Phase: Phase 2
Study type: Interventional

A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

NCT ID: NCT01900249 Completed - Clinical trials for Keratoconjunctivitis Sicca

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

DROPS
Start date: July 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.

NCT ID: NCT01817582 Completed - Clinical trials for Keratoconjunctivitis Sicca

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Start date: May 17, 2013
Phase: Phase 2
Study type: Interventional

This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine ophthalmic emulsion (Restasis) 0.05% administered BID, and Restasis 0.05% treatment alone for 12 weeks and at a follow-up safety visit 1 week post-treatment. This study will also investigate the relative efficacy of Lotemax gel 0.5% administered BID with or without Restasis 0.05% treatment administered BID and of Restasis 0.05% treatment alone for the reduction of clinical signs or symptoms of keratoconjunctivitis sicca (DED) over the first 4 weeks of a 12-week treatment period and at the end of a 12-week treatment period.